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Brussets, October 1985
THE EUROPEAN COI.II{ON IIARKET IN TIIEDICINES TAKES A NEl{ STEP FORUARD
The European common market in medicines has taken a significant step forward
with the adoption by the "Internat ltlarket" Counci I of 26 0ctober 1983 of a ne],
Directive and a Recommandation concerning medicinaL products for human consump-
ti on.
lrluch remains to be done, however, before it  is futty in operation. The European
Partiament, in its  Resolution (1) on the production  and use of pharmaceutical
products, recentty pointed out the many tasks to be accomplished in this sector,
As the Commission sees it,  reat progress has been achieved, although it  is
stiLL too sLow and taborious, in the harmonization of the [aws governing the
marketing of medicines. Thank to the new Directive and the Recommandation,
Community Legislation, which atready includes severaI directives, is strengthened
and enLarged in some important aspects :
-  the competent authorities uitI  summarize the characteristics of each medi-
cinaL product uhen it  is granted marketing authorization.
the interest of the patient, the working on the [abet wiLt be entended to
incLude the Internationat Non-proprietary  Name and the last date of use;
the standards governing the quatity of manufacture are improved;
-  mutagenisis and bio-avail-abiLity are [aid down as tro new types of test.
In addition, the Recommandation,  nhich is the resutt of five years of work
by government experts, gives a common and detaiLed interpretation of five
important aspects of Directive 751318/EEC , namety : tests for acute toxicity,
carcinogenicity, reproduction and pharmaconetics on animat subjects and the
criteria to be apptied to medicines comprising more than one active princip[e.
The new Directive strengthens the coordination of the marketing authorizations
granted by the ltlember States by improving to an appreciabte extent the present
procedure  used by the Committee for Proprietar.y trledicinaI Products:
-  this procedure is made much easier for the pharmaceuticaI companies in that,
in future, they wiLL be able present their case to the Committee oratty or
in writing and submit their apptications to two Member States instead of
to not tess than five Member States as required previouslyi
for their part, the authorities must duly take account of an authorization
atready granted by the first  ltlember State and, to this end, they uiLL be
abte to refer to at[ the orgina[ documentation  and to the officiat  summary
of the characteristics of the product. If  it  is a new medicine, they wiLL
be given access to the criticat evaluation of the dossier compited by the
first  examining  Member State i -  finat[y, the Commission wiLt now play a more active part in this Committee
by being able to seek its  advice on whether certain decisions taken by the
ltlember States reftect the provlsions of the Treaty and the criteria taid
down in the pharmaceuticat directives.
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COMMISSIONE  DELLE COMUNTTA  EUROPEE  - COMMISSIE  VAN DE EUROPESE  GEMEENSCHAPPEN-2-
5.  In spite of the progress ach'ieved today, the objective of a common market in
medicines, a desirable objective from the point of vieu of both the patients
and the pharmaceutical industry, has not yet in fact been achieved. Gonse-
quentty, the Commission wiLL, by catting for increased efforts by the competent
authorities of the ltlember States and the pharmareuticaI companies, try to secure
the recognition of the marketing authorizations  granted for.medicines,  which
it  feets, for its part, is the best means of ensuring the free movement
of medicjnes in the Community.. As and nhen necessary, the Commission vitt
put fomrard proposaLs aimed at attaining this objective.